Posted by Michael Wonder on 14 Nov 2022
UCB announces US FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
14 November 2022 - New drug application for zilucoplan seeks approval for the treatment of generalised myasthenia gravis in adult patients who are acetylcholine receptor antibody positive.
UCB today announced that the US FDA has accepted for review the new drug application for its investigational treatment, zilucoplan.
